Recipient: Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE - German Centre for Neurogenerative Diseases), Helmholtz Association
Funding: Go-Bio initial (01/10/2022 to 30/09/2023, EUR 99,998.88)

Project description:

Alzheimer's disease is responsible for 60 to 80 percent of all cases of dementia and leads to enormous financial and social burdens for everyone involved. The characteristic pathological feature of Alzheimer's disease is the insoluble deposits of tau protein, which is directly related to the decline in cognitive abilities of Alzheimer's patients. The BrainCure project team has already achieved an initial breakthrough on the way to developing a drug for the treatment of Alzheimer's disease. A chemical substance has been identified that is safe for humans, accumulates in high concentrations in the brain and inhibits the accumulation of pathogenic tau in various preclinical detection methods (assays).

The BrainCure project aims to determine the potential of the identified chemical for the treatment of Alzheimer's disease. This makes it possible to create a concrete implementation plan in order to implement the exploitation idea into a licensing scheme and possibly the founding of a company. As there is currently no effective, disease-modifying therapy for Alzheimer's, the innovative drug promises a high level of benefit for patients worldwide.